UroLift System Shows Durable, 5-Year Benefits in BPH Patients in Study, NeoTract Reports

UroLift System Shows Durable, 5-Year Benefits in BPH Patients in Study, NeoTract Reports

NeoTract has released positive, five-year follow-up data from the L.I.F.T. IDE study, evaluating the safety and effectiveness of UroLift system in men with symptomatic benign prostatic hyperplasia (BPH).

Five-year results show that UroLift, a minimally invasive procedure, effectively led to a rapid reduction of symptoms while preserving sexual function, and sustained, durable improvement in symptoms and peak urinary flow, a 50 percent improvement in quality of life, with a low retreatment rate of 2 percent to 3 percent per year.

The results were presented at the 18th annual European Association of Urology meeting (EAU’17) in London, by Claus Roehrborn, MD, a co-principal investigator for the L.I.F.T. clinical program.

“The UroLift System is truly a new standard for the treatment of BPH. This conclusion of the landmark L.I.F.T. randomized clinical trial offers high quality clinical data that demonstrate the durable benefits this unique treatment option can offer,” Roehrborn said in a press release.

“Symptom relief is achieved rapidly, within two weeks, and at one month is very similar to what can be expected at five years. Serious side effects of traditional surgery are avoided, and the UroLift System treatment is the only procedure shown to not cause sustained sexual issues,” he added.

L.I.F.T. IDE (NCT01294150) was a multicenter, randomized, patient- and outcome assessor-blinded trial of the Prostatic Urethral Lift (PUL) in men with lower urinary tract symptoms (LUTS). Published data shows that more than 86 percent of the original group of patients enrolled after four years no longer sought additional treatment for BPH.

L.I.F.T. IDE is still ongoing, but not recruiting participants. Additional data will be presented at the 2017 American Urology Association (AUA 2017) conference, taking place May 12–16 in Boston.

“This excellent long-term data reinforces our enthusiasm about the UroLift System treatment becoming the standard of care first-line treatment for men unhappy with BPH medications,” said Dave Amerson, president and chief executive officer of NeoTract.

“Adoption of the UroLift System continues to grow rapidly. We are excited to partner with urologists to help men return to normal urinary function and preserve sexual vitality with this safe and effective treatment option – the only BPH procedure that does not require cutting, heating or removal of the prostate tissue,” Amerson added.

Leave a Comment

Your email address will not be published. Required fields are marked *